Cargando…
Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes
Immunostimulatory gene therapy utilizing oncolytic viruses (OVs) as gene vehicles is a promising immunotherapy for cancer. Since viruses are immunogenic, systemic delivery can be troublesome due to neutralizing antibodies. Nevertheless, local delivery by intratumoral injection seems to induce system...
Autores principales: | Labani-Motlagh, Alireza, Naseri, Sedigheh, Wenthe, Jessica, Eriksson, Emma, Loskog, Angelica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940707/ https://www.ncbi.nlm.nih.gov/pubmed/33738337 http://dx.doi.org/10.1016/j.omto.2021.02.007 |
Ejemplares similares
-
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
por: Wenthe, Jessica, et al.
Publicado: (2020) -
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
por: Wenthe, Jessica, et al.
Publicado: (2021) -
Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles
por: Loskog, Angelica
Publicado: (2015) -
Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
por: Wenthe, Jessica, et al.
Publicado: (2023) -
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
por: Labani-Motlagh, Alireza, et al.
Publicado: (2020)